Foxd3/SLC5A6 axis regulates apoptosis in LUAD cells by controlling mitochondrial biotin uptake

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC) and its subtype lung adenocarcinoma (LUAD), is a major global health concern.
• Despite advances in targeted therapies and immune checkpoint inhibitors, treatment resistance remains a significant challenge in LUAD management.
• Novel therapeutic targets are crucial for improving patient outcomes in LUAD.

Purpose of the Study:

• To investigate the role of the SLC5A6 gene, encoding a sodium-dependent multivitamin transporter, in the progression of lung adenocarcinoma (LUAD).
• To determine the association between SLC5A6 expression levels and patient prognosis.
• To explore SLC5A6 as a potential therapeutic target for LUAD.

Main Methods:

• Analysis of SLC5A6 gene expression in LUAD tissues.
• In vitro studies involving SLC5A6 overexpression and knockout to assess effects on cell proliferation, migration, and apoptosis.
• Investigation of mitochondrial function alterations.
• Identification of transcription factors regulating SLC5A6 expression, including Foxd3.
• In vivo tumor xenograft models to evaluate the therapeutic potential of SLC5A6 inhibition.

Main Results:

• SLC5A6 is significantly upregulated in LUAD tissues and correlates with poor prognosis.
• Overexpression of SLC5A6 enhances LUAD cell proliferation and migration.
• SLC5A6 knockout impairs cell proliferation and migration, induces apoptosis, and disrupts mitochondrial function.
• Foxd3 was identified as a key transcription factor regulating SLC5A6 expression.
• In vivo experiments confirmed that SLC5A6 knockout inhibits tumor growth.

Conclusions:

• SLC5A6 plays a critical role in LUAD progression by promoting cell proliferation and migration and affecting mitochondrial function.
• SLC5A6 is a potential prognostic biomarker and a promising therapeutic target for LUAD.
• Targeting SLC5A6, potentially regulated by Foxd3, offers a novel strategy to overcome treatment resistance in LUAD.